News Agency
The Times

Yingli Pharma Announces NMPA Approval of New Anti-cancer Drug Linperlisib

  • Written by Media Outreach

The first highly selective PI3Kδ inhibitor in China

SHANGHAI, CHINA - Media OutReach - 9 November 2022 - Shanghai Yingli Pharmaceutical Co., Ltd.(the "Company" or "Yingli Pharma") is pleased to announce that linperlisib, trade name因他瑞®, a novel phosphoinositide 3-kinase delta (PI3Kδ) inhibitor, has been...

Read more: Yingli Pharma Announces NMPA Approval of New Anti-cancer Drug Linperlisib

Practical Ways to Help Reduce the Risk of Costly Business Disputes

Business disputes have a way of draining time, money and energy that could be better spent running your operation. While not every disagreement can be prevented, many disputes stem from issues that better planning may have reduced or avoided. Taking... Read more

Writers Wanted



NewsServices.com

Content & Technology Connecting Global Audiences

More Information - Less Opinion